Wang Xiaofei, Wang Zijing, Wang Jingya, Yu Yihang, Wang Yiting, Xiong Zaihuan, Han Shengna, Zhong Xiao-Bo, Wang Pei, Zhang Lirong
Academy of Medical Sciences, Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou, China; Department of Pharmacology, School of Basic Medical Sciences, Open and Key Laboratory for Pharmacogenomics at Henan Universities, Zhengzhou University, Zhengzhou, China.
Department of Pharmacology, School of Basic Medical Sciences, Open and Key Laboratory for Pharmacogenomics at Henan Universities, Zhengzhou University, Zhengzhou, China.
Mol Pharmacol. 2025 Mar;107(3):100021. doi: 10.1016/j.molpha.2025.100021. Epub 2025 Feb 7.
Ritonavir (RTV) is an important drug for anti-human immunodeficiency virus treatment and is mainly metabolized by cytochrome P450 (CYP) 3A4. Clinically, the most common side effect of RTV treatment is hepatoxicity. We previously showed that the long noncoding RNA hepatocyte nuclear factor 4 alpha (HNF4A) antisense 1 (HNF4A-AS1) negatively regulated CYP3A4 expression and participated in RTV-induced hepatotoxicity in vitro, but the mechanism has not been well understood. In this study, similar results were observed in the mouse, where liver-specific knockdown of Hnf4aos (homolog of human HNF4A-AS1) led to increased serum aspartate (∼1.8-fold) and alanine transaminase (∼2.4-fold) levels and enlarged and degenerated hepatocytes 24 hours after RTV administration. Meanwhile, endoplasmic reticulum stress markers GRP78, PDI, and XBP-1 increased about 2.4-fold, 2.1-fold, and 2.7-fold, respectively. The aggravated liver injury correlated with Hnf4aos knockdown, attributable to heightened Cyp3a11 (homolog of human CYP3A4) expression (mRNA and protein levels were 1.8-fold and 2.5-fold, respectively). Importantly, in vitro studies revealed the underlying mechanism that HNF4A-AS1 mediated the interaction between heterogeneous nuclear ribonucleoprotein C and HNF4A, whereas heterogeneous nuclear ribonucleoprotein C promoted HNF4A degradation through the ubiquitination pathway, thereby decreasing CYP3A4 expression and alleviating RTV-induced liver injury. Overall, our findings unveil a novel mechanism by which HNF4A-AS1 regulates CYP3A4 expression to influence RTV-induced liver injury. SIGNIFICANCE STATEMENT: HNF4A-AS1 negatively regulates the expression of CYP3A4, whose overexpression is highly correlated with ritonavir (RTV)-induced liver injury. In this study, the role of Hnf4aos (homolog of human HNF4A-AS1) in RTV-induced hepatotoxicity was confirmed in mice. We found that HNF4A-AS1 and HNRNPC form a complex and facilitate the ubiquitination and degradation of HNF4A protein, thereby decreasing CYP3A4 expression and alleviating RTV hepatotoxicity.
利托那韦(RTV)是抗人类免疫缺陷病毒治疗的一种重要药物,主要通过细胞色素P450(CYP)3A4代谢。临床上,RTV治疗最常见的副作用是肝毒性。我们之前表明,长链非编码RNA肝细胞核因子4α(HNF4A)反义1(HNF4A-AS1)负向调节CYP3A4表达,并参与了体外RTV诱导的肝毒性,但具体机制尚未完全明确。在本研究中,在小鼠中观察到了类似结果,给予RTV 24小时后,肝脏特异性敲低Hnf4aos(人类HNF4A-AS1的同源物)导致血清天冬氨酸(约1.8倍)和丙氨酸转氨酶(约2.4倍)水平升高,肝细胞肿大且发生变性。同时,内质网应激标志物GRP78、PDI和XBP-1分别增加了约2.4倍、2.1倍和2.7倍。肝脏损伤加重与Hnf4aos敲低相关,这归因于Cyp3a11(人类CYP3A4的同源物)表达升高(mRNA和蛋白水平分别为1.8倍和2.5倍)。重要的是,体外研究揭示了潜在机制,即HNF4A-AS1介导了不均一核核糖核蛋白C与HNF4A之间的相互作用,而异质核核糖核蛋白C通过泛素化途径促进HNF4A降解,从而降低CYP3A4表达并减轻RTV诱导的肝损伤。总体而言,我们的研究结果揭示了一种新的机制,即HNF4A-AS1通过调节CYP3A4表达来影响RTV诱导的肝损伤。意义声明:HNF4A-AS1负向调节CYP3A4的表达,其过表达与利托那韦(RTV)诱导的肝损伤高度相关。在本研究中,证实了Hnf4aos(人类HNF4A-AS1的同源物)在RTV诱导的肝毒性中的作用。我们发现HNF4A-AS1与HNRNPC形成复合物,促进HNF4A蛋白的泛素化和降解,从而降低CYP3A4表达并减轻RTV肝毒性。